There were 1,358 press releases posted in the last 24 hours and 425,444 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Biomed Industries Unveils Promising Phase 2 Results of NA-931, First Oral Quadruple Agonist for Obesity at ENDO 2025

TO:
Michael Willis
Biomed Industries, Inc.
+1 800-824-5135

FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image